Skip to main content

Table 4 Characteristics of economic evaluations by publication period

From: The economics of primary prevention of cardiovascular disease – a systematic review of economic evaluations

  1995–2000 (n = 88)
No. (%) of studies
2001–2005 (n = 107)
No. (%) of studies
1995–2005 (n = 195)
No. (%) of studies
By Study Type    
   Cost effectiveness (life years gained) 41 (47) 32 (30) 73 (37)
   Cost effectiveness (clinical outcome) 25 (28) 28 (26) 53 (27)
   Cost utility 6 (7) 32 (30) 38 (20)
   Cost consequence 11 (13) 10 (9) 21 (11)
   Cost minimization 4 (5) 3 (3) 7 (4)
   Cost benefit 1 (1) 2 (2) 3 (2)
By Perspective    
   Societal 15 (17) 23 (22) 38 (20)
   Third Party Payer 28 (32) 38 (36) 66 (34)
   Health care provider 1 (1) 3 (3) 4 (2)
   Patient 1 (1) 1 (1) 2 (1)
   Other* 3 (3) 1 (1) 4 (2)
   Not stated 40 (46) 41 (38) 81 (42)
By Funding source    
   Government 20 (23) 31 (29) 51 (26)
   Industry 22 (25) 29 (27) 51 (26)
   Foundation 10 (11) 5 (5) 15 (8)
   Other* 0 (0) 7 (7) 7 (4)
   Not stated 36 (41) 35 (33) 71 (36)
  1. * Summarized over extracted categories